Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isis Pharmaceuticals

Executive Summary

First Phase I trials of in vivo antisense product (ISIS 2105) will begin during the week of March 23. The product is being developed for the treatment of genital warts. Five dosing levels will be used to evaluate the safety of ISIS 2105, with ten volunteers receiving each dose level. The company plans to enter Phase II studies within the year, though it has not yet submitted a protocol.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel